Skip to main content
Potential Applicability of Omecamtiv Mecarbil to Patients Hospitalized for Worsening Heart Failure
The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF
Disposition and Metabolism of the Cardiac Myosin Inhibitor Aficamten in Humans
Pharmacokinetics, Excretion, and Metabolism of [14C]Aficamten Following Single Oral Dose Administration to Rats
Preclinical Pharmacokinetics of CK-4021586, a Novel Inhibitor of Cardiac Myosin, and Prediction of Human Pharmacokinetics
Cardiac Troponin Activator CK-963 Increases Cardiac Contractility in Rats
Tricuspid Regurgitation and Clinical Outcomes in Heart Failure With Reduced Ejection Fraction
Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial
Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study
Effect of Aficamten on Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The FOREST-HCM CMR Sub-study